 | |
| Clinical data | |
|---|---|
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| |
| CAS Number |
|
| PubChemCID | |
| DrugBank |
|
| ChemSpider |
|
| UNII | |
| KEGG |
|
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| ECHA InfoCard | 100.001.002 |
| Chemical and physical data | |
| Formula | C7H15NO2 |
| Molar mass | 145.202 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Emylcamate (marketed asStriatran byMerck) is ananxiolytic andmuscle relaxant. It was patented in the US in 1961 (US Patent 2,972,564) and advertised for the treatment of anxiety and tension. It was claimed to be superior tomeprobamate, which would eventually replace emylcamate.
A study of the drug's effects in mice was done in 1959. It concluded that at 50 mg/kg emylcamate gave a 63% decrease in motor activity compared with meprobamate's 32% decrease, a doubling in effective potency. The therapeutic index in mice was also established:
| Meprobamate | Emylcamate | Effect |
|---|---|---|
| 175 | 123 | ED50 (mg/kg) |
| 600 | 550 | LD50 (mg/kg) |
| 3.4 | 4.4 | Therapeutic index |
Emylcamate also has a faster intra-parenteral onset than meprobamate, 3 minutes compared with 35.[2]
Emylcamate is thecarbamate of thetertiary alcohol 3-methyl-3-pentanol. The first patented synthesis involved treating that alcohol withpotassium cyanate andtrichloroacetic acid.[3] In 1963, an improved synthesis was reported using sodium cyanate and trifluoroacetic acid.[4]
 | Thisdrug article relating to themusculoskeletal system is astub. You can help Wikipedia byexpanding it. |
 | This article about ananxiolytic is astub. You can help Wikipedia byexpanding it. |
